Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.24 USD | -0.44% | -2.09% | -47.84% |
May. 21 | JPMorgan Adjusts Teladoc Price Target to $16 From $19, Maintains Neutral Rating | MT |
Apr. 29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
Financials (USD)
Sales 2024 * | 2.66B | Sales 2025 * | 2.76B | Capitalization | 1.91B |
---|---|---|---|---|---|
Net income 2024 * | -177M | Net income 2025 * | -110M | EV / Sales 2024 * | 0.83 x |
Net Debt 2024 * | 297M | Net Debt 2025 * | 61.18M | EV / Sales 2025 * | 0.71 x |
P/E ratio 2024 * |
-10.5
x | P/E ratio 2025 * |
-16.7
x | Employees | 5,208 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.19% |
Latest transcript on Teladoc Health, Inc.
1 day | -0.44% | ||
1 week | -2.09% | ||
1 month | -11.84% | ||
3 months | -25.46% | ||
6 months | -38.04% | ||
Current year | -47.84% |
Managers | Title | Age | Since |
---|---|---|---|
Mala Murthy
CEO | Chief Executive Officer | 60 | 19-06-23 |
Jeff Nadler
CTO | Chief Tech/Sci/R&D Officer | - | 11-01-31 |
Nikolaos Nanis
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Snow
CHM | Chairman | 69 | 14-01-31 |
Sandra Fenwick
BRD | Director/Board Member | 73 | 20-11-18 |
David Shedlarz
BRD | Director/Board Member | 75 | 16-09-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.31% | 1 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 11.24 | -0.44% | 4,271,454 |
24-05-30 | 11.29 | +1.26% | 3,706,463 |
24-05-29 | 11.15 | -1.85% | 4,389,491 |
24-05-28 | 11.36 | -1.05% | 3,892,982 |
24-05-24 | 11.48 | +0.26% | 4,399,903 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.84% | 1.91B | |
+78.57% | 584M | |
+3.15% | 455M | |
-71.35% | 119M | |
-25.18% | 87.05M |
- Stock Market
- Equities
- TDOC Stock